logo
Plus   Neg
Share
Email

Alexion Pharma Announces FDA Approval Of ULTOMIRIS

Alexion Pharmaceuticals, Inc. (ALXN), on Friday, announced the U.S. FDA approved ULTOMIRIS for the treatment of adult patients with paroxysmal nocturnal hemoglobinuria, an ultra-rare blood disorder characterized by complement-mediated destruction of the red blood cells. The approval comes ahead of the PDUFA date of February 18, 2019, set by the FDA as part of an expedited eight month review.

The company noted that regulatory authorities in the EU and Japan are reviewing applications for the approval of ULTOMIRIS as a treatment for adults with paroxysmal nocturnal hemoglobinuria.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Microsoft Corp. (MSFT) founder Bill Gates has admitted that his greatest mistake was allowing Google's android to become a dominant mobile operating system. Speaking at a Economic Club of Washington luncheon, Gates said to David Rubinstein on Monday, "We're in the field of doing operating systems... McDonald's said Monday that the introduction of fresh beef at its restaurants just over one year ago has helped it gain market share in the informal eating out or IEO category for the first time in five years. In May 2018, the burger chain switched to fresh beef quarter-pound burgers from frozen beef across the U.S., as part of its efforts to provide customers with a "hotter, juicer burger." 'Toy Story 4' has broken global office box records for an animated movie, according to media reports. The movie is the fourth instalment in the 'Toy Story' series and is the sequel to 2010's 'Toy Story 3.' The Disney and Pixar film has reportedly earned $238 million after opening worldwide over the weekend and performed particularly well in Latin America and Europe.
Follow RTT